Pharmacyclics in multi-million dollar strategic alliance with France's Servier
California, USA-based drug developer Pharmacyclics has entered into a global strategic alliance with Laboratoire Servier, the leading French independent pharmaceutical company.
The collaboration will focus on the research, development and commercialization of Pharmacyclics' PCI-24781, an orally-active, novel, small-molecule inhibitor of Pan HDAC enzymes, that is currently in Phase I/II clinical trials in the USA and being developed for the treatment of solid tumors and hematologic malignancies. Pharmacyclics says it expects that this alliance will enable it to aggressively pursue its goal of developing and commercializing its innovative anti-cancer Pan HDAC inhibitor agents.
Terms of the up to $39.5 million deal
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze